Article
Medicine, General & Internal
Linda C. Giudice, Sawsan As-Sanie, Juan C. Arjona Ferreira, Christian M. Becker, Mauricio S. Abrao, Bruce A. Lessey, Eric Brown, Krzysztof Dynowski, Krzysztof Wilk, Yulan Li, Vandana Mathur, Qurratul Ann Warsi, Rachel B. Wagman, Neil P. Johnson
Summary: The effectiveness and safety of relugolix combination therapy for treating endometriosis-associated pain were evaluated in this study. The results showed that the combination therapy significantly improved symptoms and was well tolerated.
Article
Medicine, General & Internal
Emma Guttman-Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim A. Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaci, Chia-Yu Chu, H. Chih-Ho Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine
Summary: The clinical trials demonstrated that Upadacitinib may be an effective treatment option for moderate-to-severe atopic dermatitis, with a significant improvement in symptoms for most patients within 16 weeks, and both dosages were well tolerated.
Article
Gastroenterology & Hepatology
Mazen Noureddin, Shaharyar Khan, Francisco Portell, Diane Jorkasky, Jameel Dennis, Omer Khan, Lars Johansson, Edvin Johansson, Arun J. Sanyal
Summary: This study aimed to evaluate the safety and efficacy of HU6 in individuals with non-alcoholic fatty liver disease (NAFLD) and high BMI. The results showed that HU6 treatment resulted in a greater relative change in liver fat content compared to the placebo group, suggesting that HU6 could be a promising pharmacological agent for treating obesity and NAFLD and its metabolic complications.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Obstetrics & Gynecology
Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, Kentarou Kudou, Naoki Terakawa
Summary: This study evaluated the efficacy and safety of relugolix in treating endometriosis-associated pain, showing that oral administration of relugolix alleviated pain in a dose-response manner and was generally well tolerated. Relugolix demonstrated efficacy and safety comparable to leuprorelin, another treatment option.
FERTILITY AND STERILITY
(2021)
Article
Medicine, General & Internal
Andrew W. Horne, Stephen Tong, Catherine A. Moakes, Lee J. Middleton, W. Colin Duncan, Ben W. Mol, Lucy H. R. Whitaker, Davor Jurkovic, Arri Coomarasamy, Natalie Nunes, Tom Holland, Fiona Clarke, Ann M. Doust, Jane P. Daniels
Summary: This study evaluated whether oral gefitinib in combination with methotrexate is more effective than methotrexate alone in the treatment of tubal ectopic pregnancy. The results showed that oral gefitinib does not offer clinical benefit over methotrexate and increases minor adverse reactions.
Article
Biochemistry & Molecular Biology
Peter Kamstrup, Ema Rastoder, Pernille Hogh Hellmann, Pradeesh Sivapalan, Emil List Larsen, Jorgen Vestbo, Charlotte Suppli Ulrik, Jens P. Goetze, Filip Krag Knop, Jens Ulrik Staehr Jensen
Summary: Synthetic corticosteroids are commonly used for their anti-inflammatory and immunosuppressant effects, although their association with venous thromboembolism remains unclear. A trial was conducted to investigate the effects of prednisolone on haemostasis in healthy men. The results showed that prednisolone did not affect clot formation but influenced certain prothrombotic markers and antithrombotic markers.
Article
Allergy
Bruce Zuraw, William R. Lumry, Douglas T. Johnston, Emel Aygoren-Pursun, Aleena Banerji, Jonathan A. Bernstein, Sandra C. Christiansen, Joshua S. Jacobs, Karl V. Sitz, Richard G. Gower, Remi Gagnon, H. James Wedner, Tamar Kinaciyan, Roman Hakl, Jana Hanzlikova, John T. Anderson, Donald L. McNeil, Stephen B. Fritz, William H. Yang, Raffi Tachdjian, Paula J. Busse, Timothy J. Craig, H. Henry Li, Henriette Farkas, Jessica M. Best, Desiree Clemons, Melanie Cornpropst, Sylvia M. Dobo, Heather A. Iocca, Deborah Kargl, Eniko Nagy, Sharon C. Murray, Phil Collis, William P. Sheridan, Marcus Maurer, Marc A. Riedl
Summary: In the APeX-2 trial, both 110-mg and 150-mg doses of Berotralstat significantly reduced HAE attack rates compared with placebo, with good safety and tolerability profiles.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Stephen A. Harrison, Juan P. Frias, Guy Neff, Gary A. Abrams, K. Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y. Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J. Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale
Summary: The study evaluated the efficacy and safety of the bivalent Fc-FGF21 analogue Efruxifermin in patients with NASH and moderate or severe fibrosis. The results showed that Efruxifermin improved liver fibrosis and resolved NASH over 24 weeks with acceptable tolerability, supporting further assessment in phase 3 trials.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Clinical Neurology
Christos M. Polymeropoulos, Vasilios M. Polymeropoulos, Emily L. Czeisler, Michaela A. Fisher, Sandra P. Smieszek, Changfu Xiao, Gunther Birznieks, Mihael H. Polymeropoulos
Summary: This study assessed the physiological mechanism of jet lag induced by transmeridian travel and found that tasimelteon can be an effective therapeutic tool for treating jet lag disorder, improving sleep and daytime alertness.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Eugenio Mercuri, Nicolas Deconinck, Elena S. Mazzone, Andres Nascimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug-Tanguy, Nathalie Goemans, Janbernd Kirschner, Anna Kostera-Pruszczyk, Laurent Servais, Marianne Gerber, Ksenija Gorni, Omar Khwaja, Heidemarie Kletzl, Renata S. Scalco, Hannah Staunton, Wai Yin Yeung, Carmen Martin, Paulo Fontoura, John W. Day
Summary: Risdiplam has shown significant improvement in motor function compared to placebo in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Motor function generally improved in younger patients and stabilized in older patients.
Article
Infectious Diseases
Yao-Chun Hsu, Chi-Yi Chen, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Teng-Yu Lee, Ming-Shiang Wu, Ming-Jong Bair, Jyh-Jou Chen, Chieh-Chang Chen, Cheng-Hao Tseng, Chi-Ming Tai, Yen-Tsung Huang, Wen-Hui Ku, Lein-Ray Mo, Jaw-Town Lin
Summary: The study investigated the efficacy and safety of tenofovir disoproxil fumarate in reducing disease progression in patients with non-cirrhotic chronic hepatitis B and minimally raised ALT. The results showed that tenofovir disoproxil fumarate can reduce the risk of liver fibrosis progression, but its effect on necroinflammation is not significant.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Filip K. Knop, Vanita R. Aroda, Ruben D. do Vale, Thomas Holst-Hansen, Peter N. Laursen, Julio Rosenstock, Domenica M. Rubino, W. Timothy Garvey
Summary: This study assessed the efficacy and safety of oral semaglutide in overweight or obese adults without type 2 diabetes. The findings showed that oral semaglutide 50 mg once per day led to a significantly greater reduction in bodyweight compared to placebo. Gastrointestinal adverse events were the most common side effects. Oral semaglutide could be an effective option for weight management.
Article
Medicine, General & Internal
W. Timothy Garvey, Juan P. Frias, Ania M. Jastreboff, Carel W. le Roux, Naveed Sattar, Diego Aizenberg, Huzhang Mao, Shuyu Zhang, Nadia N. Ahmad, Mathijs C. Bunck, Imane Benabbad, Xiaotian M. Zhang
Summary: This study assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for weight management in individuals with obesity and type 2 diabetes. The results showed that once-weekly tirzepatide treatment significantly reduced bodyweight and achieved clinically meaningful weight loss, with a safety profile comparable to other weight management therapies.
Article
Medicine, General & Internal
David C. W. Lau, Lars Erichsen, Ann Marie Francisco, Altynai Satylganova, Carel W. le Roux, Barbara McGowan, Sue D. Pedersen, Kirsi H. Pietilainen, Domenica Rubino, Rachel L. Batterham
Summary: The study evaluated the dose-response relationship of cagrilintide in weight management, showing significant reductions in body weight in overweight and obese individuals with good tolerability.
Article
Medicine, General & Internal
Mario Castro, Edward Kerwin, David Miller, Andrew Pedinoff, Lawrence Sher, Pamela Cardenas, Barbara Knorr, David Lawrence, Diego Ossa, Wei Wang, Jorge F. Maspero
Summary: The studies did not show significant improvement in lung function or other clinical outcomes with the use of fevipiprant in patients with uncontrolled asthma, suggesting that DP2 receptor inhibition with fevipiprant may not be effective in this patient population.
